Pfizer: FDA grants priority review to XALKORI
(CercleFinance.com) - Pfizer has announced that the US Food and Drug Administration (FDA) has granted priority review of the company's Supplemental New Drug Application (sNDA) for XALKORI (crizotinib).
This is a treatment for paediatric patients with relapsed or refractory systemic large cell anaplastic lymphoma (SLCA) that is positive for anaplastic lymphoma kinase (ALK).
“Despite high survival rates for children with ALK-positive anaplastic large cell lymphoma, many will relapse, requiring novel treatment approaches,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This is a treatment for paediatric patients with relapsed or refractory systemic large cell anaplastic lymphoma (SLCA) that is positive for anaplastic lymphoma kinase (ALK).
“Despite high survival rates for children with ALK-positive anaplastic large cell lymphoma, many will relapse, requiring novel treatment approaches,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
Copyright (c) 2020 CercleFinance.com. All rights reserved.